Jamaica
· Delayed Price · Currency is JMD Elite Diagnostic Statistics
Total Valuation
Elite Diagnostic has a market cap or net worth of JMD 639.65 million. The enterprise value is 1.06 billion.
| Market Cap | 639.65M |
| Enterprise Value | 1.06B |
Important Dates
The next estimated earnings date is Monday, November 11, 2024.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Elite Diagnostic has 353.40 million shares outstanding.
| Shares Outstanding | 353.40M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 17.34% |
| Owned by Institutions (%) | 19.95% |
| Float | 150.49M |
Valuation Ratios
The trailing PE ratio is 24.46.
| PE Ratio | 24.46 |
| Forward PE | n/a |
| PS Ratio | 0.78 |
| PB Ratio | 1.25 |
| P/FCF Ratio | 6.93 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.65, with an EV/FCF ratio of 11.45.
| EV / Earnings | 40.41 |
| EV / Sales | 1.29 |
| EV / EBITDA | 4.65 |
| EV / EBIT | 11.08 |
| EV / FCF | 11.45 |
Financial Position
The company has a current ratio of 0.78, with a Debt / Equity ratio of 0.89.
| Current Ratio | 0.78 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.89 |
| Debt / EBITDA | 2.00 |
| Debt / FCF | 4.93 |
| Interest Coverage | 1.96 |
Financial Efficiency
Return on equity (ROE) is 5.25% and return on invested capital (ROIC) is 5.98%.
| Return on Equity (ROE) | 5.25% |
| Return on Assets (ROA) | 5.53% |
| Return on Capital (ROIC) | 5.98% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.76 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.16% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -2.16% |
| 50-Day Moving Average | 1.62 |
| 200-Day Moving Average | 1.63 |
| Relative Strength Index (RSI) | 57.82 |
| Average Volume (20 Days) | 57,515 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Elite Diagnostic had revenue of JMD 821.28 million and earned 26.16 million in profits. Earnings per share was 0.07.
| Revenue | 821.28M |
| Gross Profit | 543.16M |
| Operating Income | 95.37M |
| Pretax Income | 29.35M |
| Net Income | 26.16M |
| EBITDA | 198.65M |
| EBIT | 95.37M |
| Earnings Per Share (EPS) | 0.07 |
Balance Sheet
The company has 37.22 million in cash and 454.52 million in debt, giving a net cash position of -417.30 million or -1.18 per share.
| Cash & Cash Equivalents | 37.22M |
| Total Debt | 454.52M |
| Net Cash | -417.30M |
| Net Cash Per Share | -1.18 |
| Equity (Book Value) | 510.98M |
| Book Value Per Share | 1.45 |
| Working Capital | -53.33M |
Cash Flow
In the last 12 months, operating cash flow was 164.81 million and capital expenditures -72.53 million, giving a free cash flow of 92.29 million.
| Operating Cash Flow | 164.81M |
| Capital Expenditures | -72.53M |
| Free Cash Flow | 92.29M |
| FCF Per Share | 0.26 |
Margins
Gross margin is 66.14%, with operating and profit margins of 11.61% and 3.18%.
| Gross Margin | 66.14% |
| Operating Margin | 11.61% |
| Pretax Margin | 3.57% |
| Profit Margin | 3.18% |
| EBITDA Margin | 24.19% |
| EBIT Margin | 11.61% |
| FCF Margin | 11.24% |
Dividends & Yields
Elite Diagnostic does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 4.09% |
| FCF Yield | 14.43% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Elite Diagnostic has an Altman Z-Score of 1.9. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.9 |
| Piotroski F-Score | n/a |